Background Establishment of thromboembolism prevention remains a challenge despite the
widespread consensus that thromboprophylaxis safely reduces patient morbidity and …

Abstract Introduction and Objectives Novel oral anticoagulants are emerging options for the
prevention and treatment of thromboembolic diseases. They are increasingly used in clinical …

Purpose The effectiveness and tolerability of a reduced dose (110 mg) of dabigatran versus
the standard dose (150 mg) were evaluated in subgroups of patients with atrial fibrillation …

Objective: Dabigatran was the first of a new generation of anticoagulation drugs for the
indication of non-valvular atrial fibrillation (AF) to be approved. Evidence show that …

Background Warfarin reduces the risk of stroke in patients with atrial fibrillation but increases
the risk of hemorrhage and is difficult to use. Dabigatran is a new oral direct thrombin …

Oral anticoagulation is the mainstay of therapy for stroke prevention in patients with atrial
fibrillation. Vitamin K antagonists such as warfarin reduce the risk of cardioembolic stroke by …

This study aims to estimate the cost-effectiveness of dabigatran 150 mg twice daily versus
warfarin for stroke and systemic embolism risk reduction in patients with nonvalvular atrial …

Atrial fibrillation is the most common arrhythmia in over-midlife patients. In addition to
systolic heart failure, cerebral thromboembolism represents the most dramatic complication …

Objectives The primary objective was to assess the cost-effectiveness of new oral
anticoagulants compared with warfarin in patients with nonvalvular atrial fibrillation …

Background The RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy)
trial demonstrated that higher-risk patients with atrial fibrillation had lower rates of stroke or …